Lado Lado F L, Justo Firvida E, Cinos Ramos L, Calvo Gómez C, Barrio Gómez E
Servicio de Medicina Interna Hospital Comarcal de Monforte, Santiago de Compostela, La Coruña.
An Med Interna. 1992 Feb;9(2):76-80.
Seventy one mild to moderate essential hypertensive patients receiving out-patient treatment with Captopril--inhibitor of the conversion enzyme--during a period of six months, are studied. The therapeutic goal (DAP less than 95 mm Hg.) was reached in 88% of the cases, with just a single Captopril dose of 50 mg/day in 42 patients (59.1%). AP decreased from 174.2/100.2 mm Hg. to 149.2/84.0 mm Hg. (p less than 0.001). Any significant changes in heart rate nor in body weight were observed. Side effects were rare (just in two patients), although their intensity determined in both cases the interruption of treatment. Finally, and improvement in the metabolic profile of patients was observed, with reduction in glucose, cholesterol, triglycerides and uric acid at the end of the study.
对71名接受门诊治疗的轻度至中度原发性高血压患者进行了为期6个月的研究，这些患者使用血管紧张素转换酶抑制剂卡托普利进行治疗。88%的患者达到了治疗目标（舒张压低于95毫米汞柱），42名患者（59.1%）仅使用每日50毫克的单一剂量卡托普利就实现了这一目标。收缩压从174.2/100.2毫米汞柱降至149.2/84.0毫米汞柱（p<0.001）。未观察到心率和体重有任何显著变化。副作用很少见（仅在两名患者中出现），尽管在这两例中副作用的强度都导致了治疗中断。最后，观察到患者的代谢状况有所改善，研究结束时血糖、胆固醇、甘油三酯和尿酸均有所降低。
